Postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 277-280

  Takeshima, Nobuhiro ^a   Utsugi, Kuniko ^a   Hasumi, Katsuhiko ^a   Takizawa, Ken ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; Cervical cancer; Chemotherapy

Indexed keywords

CISPLATIN; EPIRUBICIN; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; SALPINGOOOPHORECTOMY; SURVIVAL TIME; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; SURVIVAL; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; POSTOPERATIVE PERIOD; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 65649088679     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819c9fa0     Document Type: Article

References (19)

1. McLellan R, Dillon MB, Woodruff JD, et al. Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery. Gynecol Oncol. 1994;52:253-259.
2. Kilgore LC, Soong SJ, Gore H, et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol. 1988;31:137-153.
3. Vesterinen E, Forss M, Nieminen U. Increase of cervical adenocarcinoma: a report of 520 cases of cervical carcinoma including 112 tumors with glandular elements. Gynecol Oncol. 1989;33:49-53.
4. Yokosuka K, Hasumi K. A clinicopathological study of the uterine cervical adenocarcinoma. J Jpn Soc Cancer Ther. 1994;29:712-719 [in Japanese].
5. Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer. 1955;76: 1948-1955.
6. Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage IB adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;79:289-293.
7. Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of IB-IIB adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surgical Oncol. 2000;26:464-467.
8. Chargui R, Damak T, Khomsi F, et al. Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol. 2006;194:43-48.
9. Peters WA 3rd, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
10. Ryu HS, Chun M, Chang KH, et al. Postoperative adjuvant concurrent chemoradiation improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol. 2005;96:490-495.
11. Iwasaka T, Kamura T, Yokoyama M, et al. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of radiotherapy. Obstet Gynecol. 1988;91:977-981
12. Lai CH, Hong JH, Hsueh S, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases. Cancer. 1999;85:1537-1546.
13. Lahousen M, Haas J, Pickel H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial. Gynecol Oncol. 1999;73:196-201.
14. Tattersall MHN, Corazon C, Coppleson. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastasis. Gynecol Oncol. 1992;46:176-181.
15. Look KY, Brunetto VL, Clarke PD, et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;63:304-311.
16. Kleine W, Rau K, Schwoeorer D, et al. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol. 1989;35: 145-149.
17. Ishikawa H, Nakanishi T, Inoue T, et al. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol. 1999;73:42-46.
18. Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate - and high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 2006;103:618-622.
19. Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005;96: 721-728.